Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases

Last updated: March 28, 2024
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Multiple Sclerosis

Treatment

18F-PBB3 PET/CT scan

Clinical Study ID

NCT06344845
PUMCH-NM-PBB3
  • Ages 49-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

In terms of the diagnostic technology of brain neurodegenerative diseases, the injection of positron tracers into the human body, so that it can combine with the corresponding protein, and show its distribution through PET imaging is a mature technology in the industry. At present, several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compounds.This clinical research project intends to display the abnormal changes of tau protein in living brain through [18F]PM-PBB3 PET imaging, which is a second-generation tracer further optimized on the basis of [11C]PBB3, and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents. Better image quality and a wider range of clinical applications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Between 45 and 90 years old; No gender limitation. Brain MRI supported the diagnosisof neurodegeneration, and there was no evidence of other neurological diseases. Informed consent signed in person by the subject or his legal guardian or caregiver.

Exclusion

Exclusion Criteria:

  • Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver,kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and otherserious diseases. Received an experimental drug or device within 1 month (whose efficacy or safety isunclear). patients who were unwilling to undergo PET/CT scans. pregnancy.

Study Design

Total Participants: 80
Treatment Group(s): 1
Primary Treatment: 18F-PBB3 PET/CT scan
Phase:
Study Start date:
November 01, 2022
Estimated Completion Date:
November 30, 2025

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.